Surgery triggers outgrowth of latent distant disease in breast Cancer: An inconvenient Truth?

Cancers

Volumn 2, Issue 2, 2010, Pages 305-337

  Retsky, Michael ^a   Demicheli, Romano ^b   Hrushesky, William ^c   Baum, Michael ^d   Gukas, Isaac ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Dormancy; Mammography; Primary antiangiogenic therapy; Surgery induced growth

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; ENDOSTATIN; FLUOROURACIL; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADJUVANT THERAPY; AFRICAN AMERICAN; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EUROPEAN AMERICAN; HEALTH CARE ACCESS; HUMAN; MAMMOGRAPHY; MASTECTOMY; METASTASIS POTENTIAL; MICROMETASTASIS; NONHUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; RACE DIFFERENCE; RECURRENCE RISK; REVIEW; TUMOR ESCAPE; TUMOR GROWTH; TUMOR SEEDING; TUMOR VASCULARIZATION;

EID: 79952253366     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020305     Document Type: Review

References (137)

1. Baum, M. Breast cancer screening comes full circle. J. Natl. Cancer Inst. 2004, 96, 1490-1491.
2. Nielsen, M.; Thomsen, J.L.; Primdahl, S.; Dyoreborg, U.; Andersen, J.A.; Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br. J. Cancer 1987, 56, 814-819.
3. National Cancer Institute FactSheet. Probability of Breast Cancer in American Women. 2006. Available online at http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer
4. Buxton, I.L.O.; Yokdang, N.; Matz, R.M. Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis, Cancer Lett. 2009, in press.
5. Stewart, I. Life's Other Secret: the New Mathematics of the Living World; Penguin Press: London, UK, 1998.
6. Ariel, I. A historical review of breast cancer treatment. In Breast Cancer: Controversies in Management; Leslie, W., Houston, J., Eds.; Futura Publishing Co.: Armonk, NY, USA, 1994.
7. Gross, S.W.; A Practical Treatise of Tumours of the Mammary Gland; D. Appelton & Co.: New York, NY, USA, 1880.
8. Greenwood, M. A Report on the Natural Duration of Cancer: Reports on Public Health and Medical Subjects, No. 33; H.M.S.O: London, UK, 1926.
9. Daland, E.M. Untreated Carcinoma of the Breast. Surg. Gynaecol. Obstet. 1927, 44, 264-271.
10. Bloom, H.J.G. Survival of women with untreated breast cancer-Past and present. In Prognostic Factors in Breast Cancer; Forrest, A.P.M., Kunkler, P.B., Eds.; E&S Livingston Ltd.: Edinburgh, German, 1968.
11. MacKay, E.N.; Sellers, A.H. Breast Cancer at the Ontario Cancer Clinics, 1938-1956, A statistical Review. Can. Med. Assoc. J. 1965, 92, 647-651.
12. Steckler, R.M.; Martin, R.G. Prolonged survival in untreated breast cancer. Am. J. Surg. 1973, 126, 111-119.
13. Halsted, W.S. The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June 1889 to January1894. Johns Hopkins Hosp. Rep. 1894, 4, 297-350.
14. DeMoulin, D. A Short History of Cancer; Martinus Nyhoff Publishers: Boston, MA, USA, 1983.
15. Virchow, R. Die Krankhaften Geschwulste; Hirshwald Publishers: Berlin, Germany, 1863-1873; Volume 1.
16. Lewis, D.; Rienhoff, W.F.J. A study of results of operations for the cure of cancer of the breast. Ann. Surg. 1932, 95, 336-400.
17. Halsted, W.S. The training of the surgeon. In Surgical Papers by William Stewart Halsted; The Johns Hopkins Press: Baltimore, MD, USA, 1924; Volume 2.
18. Urban, J. Management of operable breast cancer: the surgeon's view. Cancer 1978, 42, 2066-2077.
19. Meier, P.; Ferguson, D.J.; Karrison, T. A controlled trial of extended radical mastectomy. Cancer 1985, 55, 880-891.
20. Lacour, J.; Le, M.; Caceres, E.; Koszarowski, T.; Veronesi, U.; Hill, C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983, 51, 1941-1943.
21. Brinkley, D.; Haybittle, J.L. A 15 year follow up study of patients treated for carcinoma of the breast. Br. J. Radiol. 1968, 41, 215-221.
22. Brinkley, D.; Haybittle, J.L. The curability of breast cancer. Lancet 1975, 2, 9-14.
23. Fisher, B. Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980, 40, 3863-3874.
24. Early Breast Cancer Trialists'Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339, 1-15, 71-85.
25. Early Breast Cancer Trialists'Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of randomized trials. N. Engl. J. Med. 1995, 333, 1444-1445.
26. Nystrom, L.; Andersson, I.; Bjurstam, L.; Frisell, J.; Nordenskjöld, B.; Rutqvist, L. Long term effects of mammographic screening: updated overview of the Swedish randomized trials. Lancet 2002, 359, 909-919.
27. Gotsche, P.C.; Olsen, O. Is screening for breast cancer by mammography justifiable? Lancet 2000, 355,129-134.
28. Overgaard, M.; Hansen, P.S.; Overgaard, J.; Rose, C; Andersson, M; Bach, F; Kjaer, M; Gadeberg, C.C; Mouridsen, H.T; Jensen, M.B; Zedeler, K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 1997, 337, 949-955.
29. Ragaz, J.; Jackson, S.M.; Le, N.; Ian, H.P.; John, J.S.; Vivian, E.B.; Kenneth, S.W.; Margaret, A.K.; Christopher, M.L.C.; Marilyn, P.; Andrew, J.C.; Ivo, A.O. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997, 337, 956-962.
30. Skipper, H.E. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971, 28, 1479-1499.
31. Frei, E.III; Teicher, B.; Holden, S.A.; Cathart, K.N.S.; Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1988, 48, 6417-6423.
32. Frei, E.III; Antman, K.; Teicher, B.; Eder, P.; Schnipper, L. Bone marrow autotransplantation for solid tumours-prospects. J. Clin. Oncol. 1989, 7, 515-526.
33. Coleman, R.E.; Rubens, R.D.; Fogelman, I. Reappraisal of the baseline bone scan in breast cancer. J. Nucl. Med. 1988, 29, 1045-1049.
34. Demicheli, R.; Abbattista, A.; Miceli, R.; Valagussa, P.; Bonadonna, G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumour dormancy. Breast Cancer Res. Treat. 1996, 41, 177-185.
35. Demicheli, R.; Retsky, M.W.; Swartzendruber, D.E.; Bonadonna, G. Proposal for a new model of breast cancer metastatic development. Ann. Oncol. 1997, 8, 1075-1080.
36. Baum, M.; Chaplain, M.; Anderson, A.; Douek, M.; Vaidya, J.S. Does breast cancer exist in a state of chaos? Eur. J. Cancer 1999, 35, 886-891.
37. Retsky, M.W.; Demicheli, R.; Hrushesky, W.J.; Baum, M.; Gukas, I.D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 2008, 116, 730-741.
38. Retsky, M.W.; Demicheli, R.; Swartzendruber, D.E.; Bame, P.D.; Wardwell, R.H.; Bonadonna, G.; Speer, J.F.; Valagussa, P. Computer simulation of a breast cancer metastasis model. Breast Cancer Res. Treat. 1997, 45, 193-202.
39. Naumov, G.N.; MacDonald, I.C.; Weinmeister, P.M.; Kerkvliet, N.; Nadkarni, K.V.; Wilson, S.M.; Morris, V.L.; Groom, A.C.; Chambers, A.F. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002, 62, 2162-2168.
40. Klauber-DeMore, N.; Van Zee, K.J.; Linkov, I.; Borgen, P.I.; Gerald, W.L. Biological behavior of human breast cancer micrometastases. Clin. Cancer Res. 2001, 7, 2434-2439.
41. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
42. Schipper, H.; Turley, E.A.; Baum, M. A new biological framework for cancer research. Lancet 1996, 348, 1149-1151.
43. Schipper, H. Historic milestones in cancer biology: a few that are important in cancer treatment. Semin. Oncol. 1979, 6, 506-514.
44. Baum, M.; Vaidya, J.S.; Mittra, I. Multicentricity and recurrence of breast cancer. Lancet 1997, 349, 208.
45. Whitmore, W.F.J. The natural history of prostate cancer. Cancer 1973, 32, 1104-1112.
46. Demicheli, R.; Terenziani, M.; Valagussa, P.; Moliterni, A.; Zambetti, M.; Bonadonna, G. Local recurrences following mastectomy: support for the concept of tumour dormancy. J. Natl. Cancer Inst. 1994, 86, 45-48.
47. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
48. Folkman, J.; Watson, K.; Ingber, D.; Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
49. Folkman, J. What is the evidence that tumors are angiogenesis dependent? [editorial]. J. Natl. Cancer Inst. 1990, 82, 4-6.
50. Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West R.B.; Montgomery K.; Chi J.T.; van de Rijn M.; Botstein D.; Brown P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumours and wounds. PLoS. Biol. 2004, 2, E7.
51. Martina, H. Wound-healing genes promote cancer progression. Lancet Oncol. 2004, 5, 138.
52. Weinberg, R.A. The many faces of tumor dormancy. APMIS 2008, 116, 548-551.
53. Kumar, R.; Yarmand-Bagheri, R. The role of Her2 in angiogenesis. Semin. Oncol. 2001, 289, 27-32.
54. Tagliabue, E.; Agresti, R.; Ghirelli, C.; Morelli, C.; Menard, S. The early relapse of premenopausal patients after surgery for node positive breast cancer. Breast Cancer Res. Treat. 2001, 70, 155-156.
55. Boland G. P.; Butt I.S.; Prasad R.; Knox, W.F.; Bundred, N.J. COX-2 expression is associated with an aggressive phenotype of ductal carcinoma in situ. Br. J. Cancer 2004, 90, 423-429.
56. Giatromanolaki, A.; Koukourakis, M.I.; Kakolyris, S.; Mavroudis, D.; Kouroussis, C.; Mavroudi, C.; Perraki, M.; Sivridis, E.; Georgoulias, V. Assessment of highly angiogenic and disseminated cancer cells in the peripheral blood in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int. J. Cancer. 2004; 108, 620-627.
57. Garvin, S.; Dabrosin, C. Tamoxifen inhibits secretion of vascular endothelial growth factor in vivo. Cancer Res. 2003, 63, 8742-8748.
58. Haran, E.; Maretzek, A.; Goldberg, I.; Horowitz, A.; Degani, H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelial growth. Cancer Res. 1994, 54, 5511-5514.
59. Ehrlich, P.; Apolant, H. Beobechtungen über maligne Mäusetumoren. Berl. Klein Wchnshr 1905, 42, 871-874.
60. Bashford, E.; Murray, J.A.; Cramer, W. The natural and induced resistance of mice to the growth of cancer. Proc. R. Soc. Lond. 1907, 79, 164-187.
61. Marie, P.; Clunet, J. Fréquences des métastases viscérales chez les souris cancéreuses après ablation chirurgicale de leur tumeur. Bull. Assoc. Fr. Etud. Cancer 1910, 3, 19-23.
62. Tyzzer, E.E. Factors in the production and growth of tumor metastases. Cancer Res. Clin. Oncol. 1913, 13, 546-547.
63. Hadfield, G. The dormant cancer cell. Br. Med. J. 1954, 2, 607-610.
64. Fisher, B.; Fisher, E.R. Experimental studies of factors influencing hepatic metastases. II Effect of partial hepatectomy. Cancer 1959, 12, 929-932.
65. Fisher, B.; Fisher, E.R. Experimental studies of factors influencing hepatic metastases. III Effect of surgical trauma with special reference to liver injury. Ann. Surg. 1959, 150, 731-743.
66. Fisher, B.; Fisher, E.R. Experimental evidence in support of the dormant tumour cell. Sci. 1959, 130, 918-919.
67. Fisher, E.R.; Fisher, B. Experimental studies of factors influencing hepatic metastases. XIII Effect of hepatic trauma in parabiotic pairs. Cancer Res. 1963, 23,896-900.
68. Schatten, W.E. An experimental study of postoperative tumour metastases. 1. Growth of pulmonary metastases following total removal of primary leg tumour. Cancer 1958, 11, 455-459.
69. Schatten, W.E.; Kramer, W.M. An experimental study of postoperative tumour metastases. 2. Effect of Anesthesia, Operation, and Cortisone administration on growth of pulmonary metastases. Cancer 1958, 11, 460-462.
70. Wood, S.J.; Holyoke, E.D.; Clason, W.P.C.; Sommers, S.C.; Warren, S. An experimental study of the relationship between tumour size and number of lung metastases. Cancer 1954, 7, 437-443.
71. Paschkis, K.E.; Cantarow, A.; Stasney, J.; Hobbs, J.H. Tumor growth in partially hepatectomized rats. Cancer Res. 1955, 15, 579-582.
72. Lewis, M.R.; Cole, W.H. Experimental increase of lung metastases after operative trauma (Amputation of limb with tumour). Arch. Surg. 1958, 77, 621-626.
73. Lee, C.K. Effects of partial hepatectomy in rats on two transplantable hepatomas. Changes in weight and in synthesis of DNA and ferritin. Am. J. Pathol. 1971, 65, 347-356.
74. Alexander, J.W.; Altemeier, W.A. Susceptibility of injured tissues to haematogenous metastases: An experimental study. Ann. Surg. 1964, 159, 933-943.
75. Rudenstam, C.M. Experimental studies on trauma and metastasis formation. Acta Chir. Scand. 1968, 391 (suppl. 1), 1-83.
76. Yuhas, J.M.; Pazmino, N.H. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res. 1974, 34, 2005-2010.
77. Gorelik, E.; Segal, S.; Feldman, M. On the mechanism of tumour concomitant immunity. Int. J. Cancer 1981, 27, 847-856.
78. Gorelik, E. Resistance of tumor-bearing mice to a second tumor challenge. Cancer Res. 1983, 43, 138-145.
79. Prehn, R.T. Two competing influences that may explain concomitant tumour resistance. Cancer Res. 1993, 53, 3266-3269.
80. Simpson-Herren, L.; Sanford, A.H.; Holmquist, J.P. Effects of surgery on the cell kinetics of residual tumour. Cancer Treat. Rep. 1976, 60, 1749-1760.
81. Gunduz, N.; Fisher, B.; Saffer, E.A. Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res. 1979, 39, 3861-3865.
82. Fisher, B.; Gunduz, N.; Saffer, E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983, 43, 1488-1492.
83. Fisher, B.; Gunduz, N.; Coile, J.; Rudock, C.; Saffer, E. Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res. 1989, 49, 1996-2001.
84. Murthy, S.M.; Goldschmidt, R.A.; Rao, L.N.; Ammirati, M.; Buchmann, T.; Scanlon, E.F. The influence of surgical trauma on experimental metastasis. Cancer 1989, 64, 2035-2044.
85. Lee, J.Y.; Murphy, S.M.; Scanlon, E.F. Effect of trauma on implantation of metastatic tumour in bone in mice. J. Surg. Oncol. 1994, 56, 178-184.
86. Bogden, A.E.; Moreau, J.P.; Eden, P.A. Proliferative response of human and animal tumors to surgical wounding of normal tissues: onset, duration and inhibition. Br. J. Cancer 1997, 75, 1021-1027.
87. Abramovitch, R.; Marikovsky, M.; Meir, G.; Neeman, M. Stimulation of tumour angiogenesis by proximal wounds: spatial and temporal analysis by MRI. Br. J. Cancer 1998, 77, 440-447.
88. Abramovitch R.; Marikovsky M.; Meir G.; Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer 1999, 79, 1392-1398.
89. Hofer, S.O.; Shrayer, D.; Reichner, J.S.; Hoekstra, H.J.; Wanebo, H.J. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch. Surg. 1998, 133, 383-389.
90. O'Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lanbe, W.S.; Cao, Y.; Sage, E.H.; Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
91. Holmgren, L.; O'Reilly, M.S.; Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1, 149-153.
92. Guba, M.; Cernaianu, G.; Koehl, G.; Geissler, EK.; Jaunch, KW.; Anthuber, M.; Falk, W.; Steinbauer, M. A primary tumour promotes dormancy of solitary tumour cells before inhibiting angiogenesis. Cancer Res. 2001, 61, 5575-5579.
93. Gilead, A.; Neeman, M. The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. Int. J. Cancer 2004, 108, 524-531.
94. Naumov, G.N.; Bender, E.; Zurakowski, D.; Kang, S.Y.; Sampson, D.; Flynn, E.; Watnick, R.S.; Straume, O.; Akslen, L.A.; Folkman, J.; Almog, N. A model of human tumour dormancy: Angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst. 2006, 98, 316-325.
95. Indraccolo, S.; Stievano, L.; Minuzzo, S.; Tosello, V.; Esposito, G.; Piovan, E.; Zamarchi, R.; Chieco-Bianchi, L.; Amadori, A. Interruption of tumour dormancy by a transient angiogenic burst within the tumour microenvironment. Proc. Natl. Acad. Sci. USA 2006, 103, 4216-4221.
96. Volpert, O.V.; Lawler, J.; Bouck, N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA 1998, 95, 6343-6348.
97. Luzzi, K.J.; MacDonald, I.C.; Schmidt, E.E.; Kerkvliet, N.; Morris, V.L.; Chambers, A.F.; Groom, A.C. Multistep nature of metastatic inefficiency. Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 1998, 153, 865-873.
98. Suzuki, M.; Mose, E.S.; Montel, V.; Tarin, D. Dormant cancer cells retrieved from metastasis-free organ regain tumorigenic and metastatic potency. Am. J. Pathol. 2006, 169, 673-681.
99. Aguirre-Ghiso, J.A.; Ossowski, L.; Rosenbaum, S.K: Green fluorescent protein tagging of extracellular signal-regulated kinase and P38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 2004, 64, 7336-7345.
100. Brunschwig, A.; Southam, C.M.; Levin, A.G: Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann. Surg. 1965, 162, 416-423.
101. Lange, P.H.; Hekmat, K.; Bosl, G.; Kennedy, B.J.; Fraley, E.E. Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 1980, 45, 1498-1506.
102. Peeters, C.F.; de Waal, R.M.; Wobbes, T.; Westphal, J.R.; Ruers, T.J. Outgrowth of human liver metastases after resection of the primary colorectal tumor: A shift in the balance between apoptosis and proliferation. Int. J. Cancer. 2006, 119, 1249-1253.
103. Maniwa, Y.; Okada, M.; Ishii, N.; Kiyooka, K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998, 114, 1668-1675.
104. Ikeda, M.; Furukawa, H.; Imamura, H.; Shimizu, J.; Ishida, H.; Masutani, S.; Tatsuta, M.; Kawasaki, T.; Satomi, T. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer 2002, 5, 137-141.
105. Tagliabue, E.; Agresti, R.; Carcangiu, M.L.; Ghirelli, C.; Morelli, D.; Campiglio, M.; Martel, M.; Giovanazzi, R.; Greco, M.; Balsari, A.; Menard, S. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003, 362, 527-533.
106. Hormbrey, E.; Han, C.; Roberts, A.; McGrouther, D.A.; Harris, A.L. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin. Cancer Res. 2003, 9, 4332-4339.
107. Wu, F.P.K.; Hoeckman, K.; Meijer, S.; Cuesta, M.A. VEGF and endostatin levels in wound fluids and plasma after breast surgery. Angiogenesis 2003, 6, 255-257.
108. Meng, S.; Tripathy, D.; Frenkel, E.P.; Shete, S.; Naftalis, E.Z.; Huth, J.F.; Beitsch, P.D.; Leitch, M.; Hoover, S.; Euhus, D.; Haley, B.; Morrison, L.; Fleming, T.P.; Herlyn, D.; Terstappen, L.W.; Fehm, T.; Tucker, T.F.; Lane, N.; Wang, J.; Uhr, J.W. Circulating tumour cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10, 8152-8162.
109. Huang, S.; Ingber, D.E. A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis. 2006, 26, 27-54.
110. Rajapakse, I.; Perlman, M.D.; Scalzo, D.; Kooperberg, C.; Groudine, M.; Kosak, S.T. The emergence of lineage-specific chromosomal topologies from coordinate gene regulation. Proc. Natl. Acad. Sci. USA 2009, 106, 6679-6684.
111. Podsypanina, K.; Du, Y.C.N.; Jechlinger, M.; Beverly, L.J.; Hambardzumyan, D.; Varmus, H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321, 1841-1844.
112. Rubin, H. What keeps cells in tissues behaving normally in the face of myriad mutations? Bioassays 2006, 28, 515-524.
113. Weaver, V.M.; Petersen, O.W.; Wang, F.; Larabell, C.A.; Briand, P.; Damsky, C.; Bissell, M.J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 1997, 137, 231-245.
114. Brinster, R.L. The effect of cells transferred into the mouse blastocyst on subsequent development. J. Exp. Med. 1974, 140, 1049-1056.
115. Mintz, B.; Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA 1975, 72, 3585-3589.
116. Demicheli, R.; Retsky, M.W.; Hrushesky, W.J.M.; Baum, M. Tumor dormancy and surgery-driven dormancy interruption in breast cancer: learning from failures. Nat. Clin. Pract. Oncol. 2007, 4, 699-710.
117. Shapiro, S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J. Natl. Cancer Inst. Monogr. 1997, 22, 27-30.
118. Alexander, F.E.; Anderson, T.J.; Brown, H.K.; Forrest, A.P.; Hepburn, W.; Kirkpatrik, A.E.; Muir, B.B.; Prescott, R.J.; Smith, A. 14 years of follow-up from the Edinburgh randomised trial of breast cancer screening. Lancet 1999, 353, 1903-1908.
119. Larsson, L.G.; Andersson, I.; Bjurstam, N.; Fagerberg, G.; Frisell, J.; Tabár, L.; Nyström, L. Updated overview of the swedish randomized trials on breast cancer screening with mammography: age group 40-49 at randomization. J. Natl. Cancer Inst. Monogr. 1997, 22, 57-61.
120. Retsky, M.; Demicheli, R.; Hrushesky, W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis screening controversy. Breast Cancer Res. Treat 2001, 65, 217-224.
121. Retsky, M.; Demicheli, R.; Hrushesky, W. Breast cancer screening: Controversies and future directions. Curr. Opin. Obstet. Gynecol. 2003, 15, 1-8.
122. Bergh, J.; Jönsson, P.E.; Glimelius, B.; Nygren, P; SBU-group. Swedish council of technology assessment in health care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001, 40, 253-81.
123. Retsky, M.; Bonadonna, G.; Demicheli, R.; Folkman, J.; Hrushesky, W.; Valagussa, P. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004, 6, R372-R374.
124. Demicheli, R.; Bonadonna, G.; Hrushesky, W.J.M.; Retsky, M.; Valagussa, P. Menopausal status dependence of the timing of breast cancer recurrence following primary tumour surgical removal. Breast Cancer Res. 2004, 6, R689-R696.
125. Demicheli, R.; Miceli, R.; Moliterni, A.; Zambetti, M.; Hrushesky, W.J.; Retsky, M.W.; Valagussa, P.; Bonadonna, G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumour dormancy and mastectomy-driven acceleration of the metastatic process. Ann. Oncol. 2005, 16, 1449-1457.
126. Demicheli, R.; Retsky, M.W.; Hrushesky, W.J.; Baum, M.; Gukas, I.D.; Jatoi, I. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer 2007, 110, 1880-1888.
127. Jatoi, I.; Anderson, W.F.; Rao, S.R.; Devesa, S.S. Breast cancer trends among black and white women in the United States. J. Clin. Oncol. 2005, 23, 7836-7841.
128. Jatoi, I.; Becher, H.; Leake, C.R. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the US. Department of Defense Healthcare system. Cancer 2003, 98, 894-899.
129. Chu, K.C.; Lamar, C.A.; Freeman, H.P. Racial disparities in breast carcinoma survival rates: Seperating factors that affect diagnosis from factors that affect treatment. Cancer 2003, 97, 2853-2860.
130. Wojcik, B.E.; Spinks, M.K.; Stein, C.R. Effects of screening mammography on the comparative survival rates of African American, white, and Hispanic beneficiaries of a comprehensive health care system. Breast. J. 2003, 9, 175-183.
131. Eley, J.W.; Hill, H.A.; Chen, V.W.; Austin, D.F.; Wesley, M.N.; Muss, H.B.; Greenberg, R.S.; Coates, R.J.; Correa, P.; Redmond, C.K. et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 1994, 272, 947-954.
132. Retsky, M.W.; Demicheli, R.; Gukas, I.D.; Hrushesky, W.J. Enhanced surgery-induced angiogenesis among premenopausal women might partially explain excess breast cancer mortality of blacks compared to whites: An hypothesis. Int. J. Surg. 2007, 5, 300-304.
133. Retsky, M.W.; Hrushesky, W.J.; Gukas, I.D. Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer 2009, 9, 7-15.
134. Hanin, L.; Korosteleva, O. Does extirpation of the primary breast tumor give boost to growth of metastases? Evidence revealed by mathematical modeling. Math. Biosci. 2010, in press.
135. Zhang, Z.; Chen, D.; Fenstermacher, D.A. Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome. BMC Genomics 2007, 20,331-344.
136. Tseng, W.W.; Doyle, J.A.; Maguiness, S.; Horvai, A.E.; Kashani-Sabet, M.; Leong, S.P.L. Giant cutaneous melanomas: Evidence for primary tumour induced dormancy in metastatic sites? BMJ Case Rep. 2009 doi:10.1136/bcr.07.2009.2073.
137. Kaya, M.; Wada, T.; Nagoya, S.; Yamashita, T. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J. Orthop. Sci. 2007, 12, 562-567.